← Back
Data updated: Sep 20, 2026
LUYE INNOMIND PHARMA
Pharma Pharmaceuticals
LUYE INNOMIND PHARMA is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
LUYE INNOMIND PHARMA's Key Drugs
LUYE INNOMIND PHARMA's core commercial portfolio centers on ERZOFRI — its most strategically important drugs approved in the last 15 years.
LUYE INNOMIND PHARMA's Recent FDA Approvals
New NDA/BLA approvals for LUYE INNOMIND PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
LUYE INNOMIND PHARMA's Therapeutic Areas
Disease areas where LUYE INNOMIND PHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
LUYE INNOMIND PHARMA Pipeline Snapshot
Active clinical trials for LUYE INNOMIND PHARMA across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ERZOFRI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-07-26
- Latest
- 2025-01-22
- Applications
- 1